▎WuXiEdited by Kant Content Team

ImmunityBio Announces Positive Overall Survival (OS) Results for Its IL-15 Superagonist Anktiva (nogapendekin alfa inbakicept) in the QUILT 3.055 Study. The study involved patients with non-small cell lung cancer (NSCLC) whose disease had progressed after receiving immune checkpoint inhibitors and standard chemotherapy. These results further strengthen ImmunityBio's confidence in the potential efficacy of Anktiva as a next-generation immunotherapy across various solid and hematologic tumor types. This week, the United StatesFDA Just Approved AnktivaLaunched for the treatment of adult patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) accompanied by carcinoma in situ (CIS).Industry media Evaluate listed this therapy as one of the treatments expected to be approved this year at the beginning of the year.10 Potential Blockbuster TherapiesOne of.

ImmunityBio has scheduled a meeting with the FDA in June to discuss overall survival outcomes for PD-L1 negative and positive patients, as well as the regulatory submission pathway for second- and third-line NSCLC patients.The company will discuss participation in QUILT 3.055 during the investor conference call on April 26.Positive overall survival data from patients in the trial, which involved multiple tumor types.This meeting will also discuss the market preparation for Anktiva's recent approval for NMIBC.

Anktiva is an IL-15 superagonist. IL-15 plays a crucial role in the immune system by influencing the development, maintenance, and function of natural killer (NK) cells and immune T cells.Anktiva consists of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. It binds to the βγ T-cell receptor, directly and specifically stimulating CD8-positive T cells and NK cells while avoiding stimulation of regulatory T cells (Treg).Compared with natural, non-complex IL-15, Anktiva exhibits superior pharmacokinetic properties in patients and persists longer in lymphoid tissues, demonstrating enhanced anti-tumor activity. In 2019, Anktiva was granted Breakthrough Therapy Designation by the FDA for use in combination with BCG to treat patients with non-muscle-invasive bladder cancer in situ who previously responded poorly to BCG.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form on other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.